RecallRadar

FDA Drug recall D-0538-2021

Lamotrigine Extended-Release Tablets 250 mg 30 Tablets Rx Only NDC 49884-604-11 Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd

On 2021-06-02 the FDA classified a Class II recall of Lamotrigine Extended-Release Tablets 250 mg 30 Tablets Rx Only NDC 49884-604-11 Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd by Cardinal Health, citing CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0538-2021
ClassificationClass II
Statusterminated
Initiated2021-03-15
Published2021-06-02
Last updated2026-09-13 11:52 UTC
CompanyCardinal Health
DistributionFL, GA, SC

Product

Lamotrigine Extended-Release Tablets 250 mg 30 Tablets Rx Only NDC 49884-604-11 Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Zhejiang 317024 China For Par Pharmaceutical Companes, Inc. Spring Valley, NY 10977 U.S.A.

Reason

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Identifiers

ndc49884-561-11
ndc49884-561-01
ndc49884-561-05
ndc49884-562-11
ndc49884-562-01
ndc49884-562-05
ndc49884-563-11
ndc49884-563-01
ndc49884-563-05
ndc49884-564-11
ndc49884-564-01
ndc49884-564-05
ndc49884-604-11
ndc49884-604-01
ndc49884-604-05
ndc49884-605-11
ndc49884-605-01
ndc49884-605-05
code_info10116

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0538-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.